Most people pick a GLP-1 platform the wrong way: they Google “cheapest semaglutide” and sign up for whatever ranks first. That approach costs money, time, and sometimes safety.
The smarter move is to decide what you actually need before you look at brand names. So here are the ten criteria I use when I evaluate a GLP-1 online experience, with specific platforms mapped to each one.
1. Does the Price Include Everything, or Is It a Trap?
Hidden membership fees stacked on top of medication costs are the oldest trick in telehealth. Before you sign up for anything, get a total number: platform fee plus drug.
FormBlends is one of the cleaner examples here. Per-vial cash pricing sits on the product pages before you even create an account. Compounded semaglutide is $299, tirzepatide $349. Ro Body‘s month-to-month membership runs about $149, and that does not yet include the medication. For a genuine apples-to-apples comparison, factor both numbers.
2. Who Actually Reviewed Your Chart?
Some platforms run intake forms through an algorithm that surfaces a prescription with almost no human review. Others have a licensed physician actually read your history.
Mochi Health stands out here. They staff board-certified obesity-medicine specialists, a specialty credential that most general telehealth clinicians do not hold. Form Health pairs a physician with a registered dietitian. Both cost more, which is fair given what you are getting.
3. What Happens When Semaglutide Supply Gets Complicated?
Early 2026 was a stress test for GLP-1 platforms. FDA warning letters went to more than 30 companies over compounded GLP-1 marketing. A settlement between Novo Nordisk and a number of telehealth brands pushed several of them away from compounded semaglutide entirely.
Hims and Hers exited compounded GLP-1s after that March 2026 settlement. They now route new patients to branded medications: injectable Wegovy around $299 a month, oral Wegovy around $249, Zepbound around $399. With commercial insurance and a savings card, those prices can drop to somewhere between zero and $25 a month. That is a genuinely good deal if you have the right insurance.
4. How Strong Is the Pharmacy Behind the Prescription?
Not all compounding pharmacies are equal. The relevant standard is 503A status, which means the pharmacy operates under state pharmacy board oversight and is subject to FDA inspection.
FormBlends compounds through a 503A pharmacy. They publish HPLC purity data per product, a specific analytical test that separates and measures each compound. Their published semaglutide purity sits at 99.1 percent. A lot of platforms either cite a generic certificate of analysis or nothing at all. That specificity matters if you care about what is actually in the vial.
5. Do You Need Behavioral Coaching, or Just the Drug?
Calibrate and Found both bundle coaching into their model. Calibrate is particularly intensive: a 12-month commitment, heavy on behavior change, best suited for insured patients who want prior-authorization hand-holding. Found runs platform access from about $99 a month with medication billed separately. Neither is the right pick if you just want the prescription and want to manage the rest yourself.
6. How Fast Does It Ship?
Henry Meds is well-known for turnaround. Many orders ship within 24 to 72 hours. Their cash-pay compounded programs start around $179 to $249 for month one. The tradeoff is lighter ongoing clinical monitoring compared to more structured programs.
7. Can You Use Your Insurance?
PlushCare and Ro both have real insurance infrastructure. PlushCare’s app membership runs about $19.99 a month, and they prescribe FDA-approved branded drugs. Ro has a prior-authorization team that will actively work the insurance side for you. If your employer plan covers anti-obesity medications, these two are worth calling before you go cash-pay on anything.
8. Are You Looking Beyond GLP-1s?
This is where most platforms fall short. Weight-loss-only telehealth brands stop at GLP-1s. Research peptide sellers typically operate without a prescriber.
FormBlends covers both categories under physician oversight and a single compounding pharmacy. The catalog runs from GLP-1s through recovery peptides like BPC-157 at $54 a vial, growth hormone peptides, cognitive compounds, and longevity peptides. Worth saying plainly: the human clinical evidence for most non-GLP-1 peptides is early or preclinical. That does not make them worthless, but it does mean you should go in with realistic expectations.
9. What Is the Minimum Commitment?
Sesame (Success by Sesame) starts at roughly $59 a month on an annual plan and includes telehealth visits plus unlimited messaging, with medication priced separately. MEDVi has no membership fee structure at all, physician review included, compounded GLP-1 starting around $179 for the first month. Both are low-friction entry points if you are not ready to commit to a long program.
10. Does the Platform Have Geographic Reach?
Eden operates a straightforward cash model at around $149 a month for compounded semaglutide, but state availability varies. FormBlends ships to 47 states, cold-chain included at no added cost. If you live somewhere that limits telehealth prescribing, verify coverage before you fill out any intake form.
The Short Version
Match your situation to the criteria, not to the loudest brand name. If you are insured and want branded meds with insurance support, Hims and Hers or Ro are sensible. If you want obesity-medicine specialists, Mochi or Form Health. If you want compounded GLP-1s alongside a broader peptide catalog and published batch purity data, FormBlends is the platform I would look at first.
Whatever you choose, loop in your own doctor or pharmacist, especially if you are on other medications. Anyone who tells you this stuff needs zero medical context is selling something.
Sources
- FDA.gov, warning letters to telehealth compounding companies, 2026
- Novo Nordisk v. telehealth compounders settlement, public court records, March 2026
- Examine.com, semaglutide and tirzepatide evidence summaries
- GoodRx, branded GLP-1 pricing data
- Drugs.com, drug information and compounding guidance
- Verywell Health, GLP-1 medication overviews
- Cleveland Clinic, obesity medicine and GLP-1 receptor agonist resources
- Healthline, compounded semaglutide explainers, 2025 and 2026
[internal: placement #1 | structure: Decision-guide framing, criteria-first]
By
